Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Return on Capital Employed for 5 consecutive years, with 0.16% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 4.0% to 0.16% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.16%, a 4.0% decrease, with the full-year FY2025 number at 0.16%, down 2.0% from a year prior.
  • Return on Capital Employed was 0.16% for Q4 2025 at Janux Therapeutics, down from 0.14% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.05% in Q3 2021 to a low of 0.23% in Q2 2023.
  • A 5-year average of 0.15% and a median of 0.14% in 2025 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: decreased -12bps in 2022, then increased 14bps in 2024.
  • Janux Therapeutics' Return on Capital Employed stood at 0.09% in 2021, then tumbled by -115bps to 0.19% in 2022, then decreased by -4bps to 0.2% in 2023, then surged by 42bps to 0.11% in 2024, then tumbled by -39bps to 0.16% in 2025.
  • Per Business Quant, the three most recent readings for JANX's Return on Capital Employed are 0.16% (Q4 2025), 0.14% (Q3 2025), and 0.14% (Q2 2025).